Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 Study 302)

NCT07455383 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT07455383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07455383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 Study 302)
Lead sponsor
Alkermes, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
April 6, 2026
Completion date
June 30, 2027
Enrollment
150 (estimated)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

narcolepsy type 1